PK Evaluation In Pregnancy: Can HIV Show A Way Forward?

US FDA workshop on efforts to advance pharmacokinetic data collection in pregnant women highlights the (slow-moving) antiretroviral experience, but COVID therapies show that regulatory receptiveness is a poor match for recruitment and liability concerns.

pregnancy and research
• Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

More from R&D

More from Pink Sheet